Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics - PubMed

Affiliations

• PMID: 1703351

Review

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics

T E Starzl et al. Transplant Proc. 1991 Feb.

Abstract

FK 506 is a superior immunosuppressive agent that should improve the grafting of organs that already are part of our every day transplant practices, as well as those which are presently impractical. Immune intervention for serious autoimmune diseases also should be a more attractive option with this drug. Lessons are still being learned about dosage and what determines safe dose schedules. At a basic level, the study of FK 506 and its comparison to CyA may have shed light on mechanisms and characteristics of the whole class of so-called macrolide immunosuppresants and their cytosolic binding sites.

Similar articles

• A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

  Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. Siekierka JJ, et al. Nature. 1989 Oct 26;341(6244):755-7. doi: 10.1038/341755a0. Nature. 1989. PMID: 2477714

• Immunosuppression. Convergence of drug action.

  Freedman RB. Freedman RB. Nature. 1989 Oct 26;341(6244):692. doi: 10.1038/341692a0. Nature. 1989. PMID: 2477712 No abstract available.

• Immunosuppression. Binding by design.

  Ringe D. Ringe D. Nature. 1991 May 16;351(6323):185-6. doi: 10.1038/351185a0. Nature. 1991. PMID: 1710317 No abstract available.

• Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases.

  Kay JE. Kay JE. Biochem J. 1996 Mar 1;314 ( Pt 2)(Pt 2):361-85. Biochem J. 1996. PMID: 8670043 Free PMC article. Review. No abstract available.

• Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506?

  Sigal NH, Dumont FJ, Siekierka JJ, Wiederrecht G, Parent SA, Brizuela L. Sigal NH, et al. Transplant Proc. 1991 Dec;23(6):2846-9. Transplant Proc. 1991. PMID: 1721295 Review. No abstract available.

Cited by

• Practical aspects of FK 506 analysis (Pittsburgh experience).

  Warty VS, Venkataramanan R, Zendehrouh P, Mehta S, McKaveney T, Flowers J, Zuckerman S, Krajak A, Zeevi A, Fung, et al. Warty VS, et al. Transplant Proc. 1991 Dec;23(6):2730-1. Transplant Proc. 1991. PMID: 1721259 Free PMC article. No abstract available.

• Strategy of FK 506 therapy in liver transplant patients: effect of graft function.

  Abu-Elmagd KM, Fung JJ, Alessiani M, Jain A, Takaya S, Venkataramanan R, Warty VS, Shannon W, Todo S, Tzakis A, et al. Abu-Elmagd KM, et al. Transplant Proc. 1991 Dec;23(6):2771-4. Transplant Proc. 1991. PMID: 1721272 Free PMC article. No abstract available.

• Recent advances in hepatic transplantation at the University of Pittsburgh.

  Abu-Elmagd K, Bronsther O, Jain A, Irish W, Ramos H, Marino IR, Dodson F, Selby R, Doyle H, Furukawa H, et al. Abu-Elmagd K, et al. Clin Transpl. 1993:137-52. Clin Transpl. 1993. PMID: 7522528 Free PMC article.

• One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.

  Jain AB, Fung JJ, Todo S, Reyes J, Selby R, Irish W, Doyle H, Abu-Elmagd K, Casavilla A, Nour B, et al. Jain AB, et al. Transplant Proc. 1995 Feb;27(1):1099-104. Transplant Proc. 1995. PMID: 7533353 Free PMC article. No abstract available.

• Cytotoxic effects of FK506 on human renal proximal tubule cells in culture.

  Atcherson MM, Trifillis AL. Atcherson MM, et al. In Vitro Cell Dev Biol Anim. 1994 Sep;30A(9):562-7. doi: 10.1007/BF02631253. In Vitro Cell Dev Biol Anim. 1994. PMID: 7529625

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information